Cell News and Research

RSS

Aquaporin AQP10 retains transport ability even when carbohydrate structure is removed

Water channels exist not only in nature - microscopical water channels are also present in the cells of the body, where they ensure that water can be transported through the protective surface of the cell. Scientists at the University of Gothenburg, Sweden, have discovered that one type of the body's water channels can be modified such that it becomes more stable, which may be significant in the treatment of several diseases.

11 Oct 2011

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers - combine them with inhibitors of the MEK/ERK signaling pathway.

11 Oct 2011

Tantalizing glimmers about roles of CCR2 gene, Th17 cell and a missing monocyte

An estimated 1.3 million people in the United States suffer from rheumatoid arthritis. The causes behind this chronic disease — which can exhibit itself as pain, swelling, stiffness, deformation, and loss of function in the joints — have eluded scientists for centuries. A new study by UNC researchers offers tantalizing glimmers about the roles of a gene called CCR2, an immune system cell called Th17 cell, and a missing monocyte.

11 Oct 2011

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

WTSI announces new technique to reprogramme human cells

Researchers from the Wellcome Trust Sanger Institute today announce a new technique to reprogramme human cells, such as skin cells, into stem cells. Their process increases the efficiency of cell reprogramming by one hundred-fold and generates cells of a higher quality at a faster rate.

11 Oct 2011

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Aduro BioTech, Inc. announces the treatment of the first patient in the Phase 2 pancreatic cancer clinical trial of the sequential administration of two cancer vaccines: Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine.

11 Oct 2011

Nexcelom to distribute FCS Express 4 Cytometry Software

De Novo Software, a leading provider of flow and image cytometry data analysis solutions, and Nexcelom Bioscience, a leading supplier of cell counting and analysis products for bioresearch and drug discovery, announced today a licensing agreement enabling Nexcelom to distribute De Novo Software's flagship product, FCS Express 4 Software.

11 Oct 2011

Troy High School teacher receives top prize in national ING Unsung Heroes awards program

ING, a leading provider of employer-sponsored retirement plans for educators, businesses, and government and not-for-profit entities, announced that Rebecca Brewer, a biology teacher at Troy High School in Troy, Mich., has received the top prize in the national 2011 ING Unsung Heroes awards program. Through this program, ING awards educators throughout the U.S. grants for innovative teaching ideas.

11 Oct 2011

Scripps Research receives NIH grant to determine how HCV induces liver cancer

The Scripps Research Institute has been awarded a $2.2 million grant by the National Institutes of Health (NIH) to determine how the hepatitis C virus (HCV) induces liver cancer.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

Roche's gantenerumab removes amyloid plaques from the brain of patients with AD

Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.

11 Oct 2011

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

11 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

11 Oct 2011

Four-gene signature may predict patients at higher risk of OSCC recurrence

Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence.

11 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

FDA to review Banner's Bexarotene ANDA for CTCL skin cancer treatment

Banner Pharmacaps Inc. has confirmed that its Abbreviated New Drug Application for Bexarotene 75 mg soft gelatin capsules, a generic version of Targretin, has been accepted for review by the US Food and Drug Administration.

11 Oct 2011

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

DNA vaccine development company Coridon Pty Ltd. today announced that it had successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with outstanding results. The company will now look to progress the program into clinical studies.

10 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011

Unither Virology receives NIAID contract for glycobiology antiviral platform

United Therapeutics Corporation announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.

10 Oct 2011